74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
PTC Therapeutics Inc
Closed
Sector Healthcare
50.62 0.68
Overview
Share price change
24h
Min
50.45
Max
51.08
Income | -7.5M -107M |
|---|---|
Sales | 10M 197M |
EPS | -1.39 |
Profit margin | -54.198 |
Employees | 988 |
EBITDA | -19M -55M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +20.34 upside |
Next Earnings | 27 Feb 2025 |
|---|
Market Cap | 374M 3.9B |
|---|---|
Previous open | 49.94 |
Previous close | 50.62 |
News Sentiment
By Acuity
50%
50%
157 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
PTC Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
PTC Therapeutics Inc Forecast
Price Target
By TipRanks
20.34% upside
12 Months Forecast
Average 61 USD 20.34%
High 113 USD
Low 41 USD
Based on 13 Wall Street analysts offering 12 month price targets forPTC Therapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
157 / 393 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About PTC Therapeutics Inc
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).
